The acquisition will enable BAL to leverage SFCL s proficiency in developing cost-effective and distinctive manufacturing routes for off-patent molecules, it said. "This acquisition involves obtaining a 100 per cent stake through cash consideration, with an estimated enterprise value of Rs 139 crores based on the valuation," the Delhi-based BAL said in a statement.
The company said the licensed manufacturer and reseller model will allow 3M India to continue to have exclusive access to the health care products and IP portfolio of the new entity and to continue to participate in the growing health care market in India. The distribution model will permit 3M India to act as an independent exclusive distributor of the new entitys products in India, ensuring continued leverage for the health care business.
Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of its overarching strategy to strengthen its IP portfolio further. What Happened: The patent application refers to the psychedelic molecule 3-Methylmethcathinone (3-MMC) as a potential treatment for Dyskinesia and expands Clearmind's portfolio for innovative molecules, new indications, and treatments